Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04964934
Title Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + AZD9833

Letrozole + Palbociclib

Abemaciclib + Letrozole

Anastrozole + Palbociclib

Abemaciclib + Anastrozole

AZD9833 + Palbociclib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.